Phosphatidylinositol 4-kinase (Cryptosporidium) (PI4K)

Phosphatidylinositol 4-kinase (Cryptosporidium) is a lipid kinase enzyme crucial for cell signaling and membrane trafficking in eukaryotic cells. It catalyzes the phosphorylation of phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PI4P), which is a key metabolic precursor for higher phosphorylated inositol lipids and regulates crucial signaling pathways. In Cryptosporidium, PI4K is an essential enzyme for parasite survival and pathogenesis, making it a validated therapeutic target for cryptosporidiosis. Selective PI4K inhibitors, such as EDI048, have shown high potency and gut-restricted action for anti-Cryptosporidium therapy, exploiting structural differences between the parasite and host enzyme at the ATP-binding pocket to achieve selectivity[2][3]. Drug resistance can arise from point mutations in key active site residues[3]. PI4K is thus central to novel anti-parasitic drug strategies with particular importance in pediatric and immunocompromised populations where cryptosporidiosis is most severe[2][3].

Other names

Phosphatidylinositol-4-kinasePI(4)KCpPI4K

Inhibition of ATP-binding site to block lipid kinase activity[3]